The 400-Member Protein Family That Neuroscience Has Almost Entirely Ignored
Nature Reviews Drug Discovery identifies SLC transporters as untapped CNS drug targets, but 97% remain undrugged, and trial designers...
CNS Drug Development
The FDA Just Handed Industry a Rulebook on AI in Trials. Now Comes the Hard Part.
FDA and EMA published coordinated AI frameworks in 2025-2026, but sponsor comment letters reveal the real debate: do these...
The Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and...
SCI-110’s Phase IIb in Tourette Syndrome: What Hannover Tells Us About Cannabinoid Trial Design in CNS
NeuroThera Labs activates Hannover Medical School for SCI-110 Phase IIb in adult Tourette Syndrome, building on a 21% tic...
The FDA’s Psychedelic Guidance Is Really a Study-Design Reckoning
The FDA's July 2026 psychedelic guidance is nonbinding on paper. In practice it tells psilocybin, LSD, and MDMA developers...
The Trial Architecture Neurodegenerative Disease Has Always Needed — And Kept Refusing to Build
MAMS platform trials could end neurology's 99.6% drug failure rate. The Lancet just made the case. Here's what the...